ASA. G. Sukhotina

A. G. Sukhotina

*This is an algorithmically generated author record based on publicly available information.

A. G. Sukhotina has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Using ammonium glycyrrhizinate as part of combination therapy for moderate to severe atopic dermatitis in children

    by A. S. Stadnikova, O. B. Tamrazova, G. A. Novik, A. G. Sukhotina, I. V. Goncharova, А. С. Стадникова, О. Б. Тамразова, Г. А. Новик, А. Г. Сухотина, Л. В. Гончарова

    Introduction . Atopic dermatitis (AD) in children is characterized by a chronic relapsing course, marked pruritus, sleep disturbance, and reduced quality of life. In patients with moderate-to-severe disease, there remains a need for additional anti-inflammatory approaches that improve symptom control and reduce the need for treatment escalation. Aim . To evaluate the use of the anti-inflammatory drug ammonium glycyrrhizinate (Reglisam, VIFITECH, Russia) in combination therapy and in the prevention of AD exacerbations in children with moderate-to-severe disease. Materials and methods. An open-label, prospective, observational comparative study was conducted on 60 patients aged 2–17 years with moderate-to-severe AD. The main group included 30 children who received standard therapy combined with Reglisam for 84 days; the comparison group included 30 children who received standard therapy alone. SCORAD index, clinical symptoms, pruritus, sleep disturbance, quality of life assessed by CDLQI, need for additional therapy, and safety were evaluated. Results . In the main group, a significant reduction in AD activity was observed: by day 84, the SCORAD index was 55% lower than in the comparison group (p < 0.001). By the end of follow-up, mild degree of disease was observed in 90.0% of patients in the main group and in 23.3% of patients in the comparison group. During Reglisam therapy, the extent and severity of skin lesions, inflammatory manifestations, pruritus, and sleep disturbances decreased, and quality of life improved. AD exacerbations occurred less frequently (33% vs 93%), and the need for topical glucocorticosteroids and antihistamines was lower. No adverse events related to Reglisam were reported. Conclusion . The addition of the anti-inflammatory drug Reglisam to standard therapy for moderate-to-severe AD in children aged 2–17 years may be considered an effective and well-tolerated component of comprehensive treatment and prevention of disease exacerbations.

  • Open Access

    Efficacy and safety of amino acid-based formulas in the management of infants with cow’s milk protein allergy: an open-label prospective controlled study

    by G. A. Novik, O. B. Tamrazova, A. G. Sukhotina, A. V. Tamrazova, M. V. Zhdanova, Г. А. Новик, О. Б. Тамразова, А. Г. Сухотина, А. В. Тамразова, М. В. Жданова

    Aim. To determine the efficacy and safety of long-term use of an amino acid-based formula in children with cow›s milk protein allergy (CMPA) and moderate to severe atopic dermatitis (AD). Materials and methods. The study included 60 children under 12 months of age with CMPA presenting with cutaneous symptoms (moderate or severe AD according to the oSCORAD) and/or gastrointestinal symptoms. Prior to the study, all patients were prescribed an extensively hydrolyzed formula (EHF) for 4 weeks. Patients with no or incomplete response to EHF ( n = 30) were assigned to Group 1, receiving an amino acid-based formula (AAF) for 12 months. The 30 patients who showed a positive response to EHF were assigned to Group 2. Results. Children in Group 1 showed greater gains in weight and height during the first 6 months compared to children in Group 2 ( p < 0.001). The resolution of gastrointestinal symptoms in children receiving AAF was observed within 14 days along with an improvement in the clinical picture of AD within 3–5 days. Also, both groups showed a decrease in oSCORAD and EASI scores; however, children receiving AAF had a significantly smaller number of exacerbations ( p = 0.041) and a lower impact of dermatosis on daily activities ( p = 0.002). After 6 months of therapy, 53.3% of children in Group 1 developed tolerance to cow’s milk proteins, compared to only 23.3% in Group 2 ( p = 0.017). After 2 years of follow-up, tolerance was noted in all children who received AAF versus 87.7% of those fed with EHF. Conclusion. The use of AAF in children with CMPA is an effective dietary management method that leads to faster resolution of gastrointestinal symptoms, improvement in the course of atopic dermatitis, and prolongation of its remission. It shortens the period for tolerance development, has a positive effect on the child›s physical development, and contributes to a significant improvement in the quality of life of both patients and their parents.

  • Open Access

    Recognizing secondary infection in patients with atopic dermatitis: Head & neck atopic dermatitis

    by O. B. Tamrazova, A. V. Tamrazova, G. A. Novik, M. V. Zhdanova, A. S. Stadnikova, A. G. Sukhotina

    Atopic dermatitis is a hereditary chronic skin disease characterized by severe itching, recurrent course and association with other diseases of atopic nature, as well as numerous complications, which include the addition of a secondary infection. Head and neck atopic dermatitis (HNAD) is a special phenotype of atopic dermatitis that occurs in adolescents and adults. A characteristic feature of HNAD is the lesion of skin areas rich in sebaceous glands (face, neck, upper third of the chest and back), which is associated with the active participation of Malassezia fungi in the pathogenesis of the dermatosis. The multifactorial pathogenesis of HNAD, often persistent course, the impossibility of complete elimination of the provoking factor, as well as the addition of a secondary bacterial infection against the background of itching, necessitate a comprehensive approach to the treatment of this condition and the use of combination drugs containing a glucocorticosteroid, an antimycotic and an antibiotic to relieve exacerbations. The article examines the etiology, mechanisms of development of HNAD, clinical features, as well as modern methods of therapy, the practical application of which is demonstrated in a clinical example: patient, 19 years old, complaining of itchy, flaky rashes in the face and neck area, existing for 3 weeks. Based on the clinical picture, a diagnosis was made: atopic dermatitis of the face and neck. Given the multifaceted cause of the condition, namely the participation of both a pronounced immune response characteristic of AD, active colonization by Malassezia fungi, as well as open “gates” for secondary bacterial infection in the form of erosions, the prescription of a topical glucocorticosteroid was pathogenetically justified.

  • POSSIBILITIES FOR THE USE OF PIMECROLIMUS IN THE TREATMENT OF ATOPIC DERMATITIS IN CHILDREN

    by O.B. Tamrazova, Moscow Z.A. Bashlyaeva Children’s City Clinical Hospital, G.A. Novik, A.V. Tamrazova, G.E. Bagramova, A.G. Sukhotina

    Atopic dermatitis is a common chronic skin disease that is always accompanied by itching and has a significant impact on the patient's quality of life. The goal of therapy for atopic dermatitis, like any chronic dermatosis, is to achieve stable remission, which, given the nature of the disease, can be achieved with the help of a drug that has anti-inflammatory potential and a high safety profile. The therapeutic options for the use of pimecrolimus in patients with atopic dermatitis are observed in the Article.

  • Open Access

    Therapeutic potential of the treatment and control of severe recurrent atopic dermatitis

    by O. B. Tamrazova, A. S. Stadnikova, G. A. Novik, A. G. Sukhotina, А. С. Воробьева, G. E. Bagramova, A. A. Bezukladnova

    Atopic dermatitis is a hereditary inflammatory skin disease characterized by pruritus, a long recurrent course and certain evolutionary dynamics. Atopic dermatitis of moderate and severe severity is considered a systemic disease that exacerbates the course of associated pathologies, including cardiovascular, neuropsychiatric, and malignant diseases. The current paper presents the essentials about moderate and severe severity atopic dermatitis, statistical epidemiologic and pathogenetic data is thoroughly processed, the issues of the quality of life of such patients are especially accentuated. It is known that a few years ago the therapy of moderate and severe atopic dermatitis was based on systemic corticosteroids and classical immunosuppressants, but they had limited efficacy and were not suitable for long-term treatment due to their safety profile. This article highlights the development of new effective and easy-to-use therapies for atopic dermatitis, which led to the emergence of selective Janus kinase inhibitors. The review presents the way selective inhibitors of Janus kinases works and their effect on the barrier function of the skin. The paper provides the research data on the very first drug from the group of selective inhibitors - upadacitinib, which proved its efficacy on a par with a high degree of safety. The authors presented their own clinical observation of the use of upadacitinib in adolescents with severe atopic dermatitis. The use of upadacitinib in the described clinical cases led to a decrease in the severity of subjective and objective symptoms of inflammatory skin diseases.